Matthew Herper on Muck Rack

Matthew Herper Verified

New York
Senior Editor — Forbes
As seen in:  Forbes

Forbes reporter covering science and medicine

A Giant Genetic Portrait Of Iceland Gives A Glimpse Of Medicine's Future

forbes.com — It's the most complete genetic map of an entire country yet completed - and it could show clues of what medicine could look like in the coming age of big data. Researchers working at DeCode Genetics, a unit of the drug company Amgen, have sequenced the genomes of 2,636 Icelanders and [...]

New Patent Law Would Trash Disease Cures

forbes.com — If you listen to large tech companies, they will tell you they are in dire need of another bailout from scary "patent trolls" who burden them with frivolous lawsuits. This tech bailout will come in the form of a bill that would weaken 225 years of U.S. patent law to [...]

Biogen Drug Could Inspire New Hope For Alzheimer's Treatments

forbes.com — An experimental Alzheimer's treatment being developed by biotechnology firm Biogen Idec seemed to slow patients' inexorable cognitive decline in a small, preliminary study. The result will probably lead to greater hope for a new strategy for drug companies: Treat Alzheimer's patients early, when the disease is mild, and use brain imaging [...]

In Big Shift, 23andMe Will Invent Drugs Using Customer Data

forbes.com — 23andMe CEO and Founder Anne Wojcicki 23andMe, the Google-backed personal genetics startup, will no longer just sell tests to consumers, or genetic data to pharmaceutical companies. This morning, it announced that it plans to start inventing medicines itself. It's not just talk. The company has hired Richard Scheller, who led drug discovery [...]

Dendreon Disclosure May Endanger Provenge Study

forbes.com — Has Dendreon , a money-losing drug developer, imperiled the main study of its experimental prostate cancer treatment Provenge? On Oct. 6, Dendreon put out a press release that sent its shares up 33% in a day. Provenge appeared to cut patients' death rates by 20% compared with a placebo treatment, the company said.

Top FDA Official Says Orexigen Data Unreliable, Likely False

forbes.com — The data showing that Orexigen's obesity drug Contrave reduced the risk of heart attacks and cardiovascular death and sent shares of the tiny La Jolla, Calif., biotechnology company soaring 30% were probably "unreliable," "misleading," and "likely false," according to a top Food and Drug Administration official. If Orexigen cannot find way [...]

Bill And Melinda Gates Foundation Makes Largest Ever Equity Investment In A Biotech Company

forbes.com — The Bill & Melinda Gates Foundation is investing $54 million in CureVac, a German company involved in making vaccines. It is the largest ever investment by the foundation in a company, reflecting a new strategy of not just giving grants but supporting and having a stake in businesses. The investment, part [...]

Orexigen Comments On Data Disclosure That "Disappointed" FDA

forbes.com — Earlier today, Forbes contributor Larry Husten was first to report that Orexigen had released glowingly positive, but preliminary, cardiovascular data from a study of its obesity drug, Contrave, against the wishes of the study's lead investigator, potentially endangering the final result of the trial. The Food and Drug Administration issued a statement [...]

The FDA Will Force Orexigen To Do A Second Safety Study Because Of Contrave Disclosures

forbes.com — Orexigen's failure to keep a lid on a key safety analysis of its obesity drug Contrave will lead the Food and Drug Administration to force it to do a second study in order to prove that the medicine is safe for the heart. The FDA made the decision even before Orexigen [...]

Has Orexigen Has Endangered Its Future To Boost Its Stock?

forbes.com — Obesity drug maker Orexigen Therapeutics disclosed this morning that early data from a study of its drug Contrave seem to show that not only does the medicine not cause heart attacks, as some feared, but that it may actually prevent them. That's amazing news, and it sent Orexigen shares up 46% [...]
More Articles →
Mar 26, 2015

@jamesashchem @Dereklowe I think it's probably at least as much the writer as the company.

Mar 26, 2015

@adamfeuerstein You could get a cupcake at Magnolia. There's a Pret right there. More seriously, there's a bunch of Irish pubs near there.

Mar 26, 2015

RT @SecBurwell: #Opioid drug abuse is a devastating epidemic facing our nation. @HHSGov is ready to tackle this crisis: 1.usa.gov/1HOHVcd.

Mar 26, 2015

@King__Trev I tend to expect that PCSK9s will yield greater benefits than statins.

Mar 26, 2015

@adamfeuerstein but if you call them "armored CARTS" it sounds like you're playing the Wii U.

Mar 26, 2015

RT @bradloncar: Mac Cheever from The Hutch has a slide that shows how experts voted for the most promising I-O agents. pic.twitter.com/bH5Bq2LfER

Mar 25, 2015

So @HansBishop1 talked with @megtirrell about the op-ed he wrote about patent laws for Forbes. Go watch: video.cnbc.com/gallery/?video…

Email Matthew by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile